In NSTE-ACS patients , the primary endpoint was reduced with ticagrelor vs. clopidogrel [ 10.0 vs. 12.3 % ; hazard ratio ( HR ) 0.83 ; 95 % confidence interval ( CI ) = 0.74-0 .93 ] , as was myocardial infarction ( 6.6 vs. 7.7 % ; HR 0.86 ; 95 % CI = 0.74-0 .99 ) , cardiovascular death ( 3.7 vs. 4.9 % ; HR 0.77 ; 95 % CI = 0.64-0 .93 ) , and all-cause death ( 4.3 vs. 5.8 % ; HR 0.76 ; 95 % CI = 0.64-0 .90 ) .